Removal of senescent cells reduces the viral load and attenuates pulmonary and systemic inflammation in SARS-CoV-2-infected, aged hamsters

Lou Delval,Aline Hantute-Ghesquier,Valentin Sencio,Jean Michel Flaman,Cyril Robil,Fabiola Silva Angulo,Larissa Lipskaia,Ozmen Çobanoğlu,Anne-Sophie Lacoste,Arnaud Machelart,Adeline Danneels,Mathieu Corbin,Lucie Deruyter,Séverine Heumel,Thierry Idziorek,Karin Séron,Florent Sauve,Antonino Bongiovanni,Vincent Prévot,Isabelle Wolowczuk,Sandrine Belouzard,Jean-Michel Saliou,Philippe Gosset,David Bernard,Yves Rouillé,Serge Adnot,Martine Duterque-Coquillaud,François Trottein
DOI: https://doi.org/10.1038/s43587-023-00442-w
2023-07-08
Nature Aging
Abstract:Older age is one of the strongest risk factors for severe COVID-19. In this study, we determined whether age-associated cellular senescence contributes to the severity of experimental COVID-19. Aged golden hamsters accumulate senescent cells in the lungs, and the senolytic drug ABT-263, a BCL-2 inhibitor, depletes these cells at baseline and during SARS-CoV-2 infection. Relative to young hamsters, aged hamsters had a greater viral load during the acute phase of infection and displayed higher levels of sequelae during the post-acute phase. Early treatment with ABT-263 lowered pulmonary viral load in aged (but not young) animals, an effect associated with lower expression of ACE2, the receptor for SARS-CoV-2. ABT-263 treatment also led to lower pulmonary and systemic levels of senescence-associated secretory phenotype factors and to amelioration of early and late lung disease. These data demonstrate the causative role of age-associated pre-existing senescent cells on COVID-19 severity and have clear clinical relevance.
What problem does this paper attempt to address?